CLVS Clovis Oncology Inc.

20.15
-0.73  -4%
Previous Close 20.88
Open 20.67
Price To Book 7.27
Market Cap 1065301806
Shares 52,868,576
Volume 280,081
Short Ratio
Av. Daily Volume 1,649,767

NewsSee all news

  1. Clovis Focuses on Rubraca Label Expansion, Competition Stiff
  2. Company News For Apr 16, 2019
  3. Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment
  4. Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
  5. Analysts, Options Traders Swarm Sinking CLVS Stock

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 data to be presented fall 2019.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Phase 3 confirmatory trial is enrolling.
Rucaparib ARIEL4
Relapsed ovarian cancer patients with BRCA mutations
Phase 2 data presented at AACR April 2019. PFS 9.1 months.
Rucaparib
Platinum-sensitive pancreatic cancer

Latest News

  1. Clovis Focuses on Rubraca Label Expansion, Competition Stiff
  2. Company News For Apr 16, 2019
  3. Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment
  4. Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
  5. Analysts, Options Traders Swarm Sinking CLVS Stock
  6. Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
  7. Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report
  8. Clovis Oncology, Conduent, Edison International and More: Here’s What The Smart Money Thinks of These Market Movers
  9. Clovis Oncology halts mid-stage bladder cancer trial, shares drop
  10. AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
  11. Clovis Posts Data on Rubraca Study for Pancreatic Cancer
  12. Advaxis Up on Positive Early-Stage Immunotherapy Study Data
  13. Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
  14. Implied Volatility Surging for Clovis (CLVS) Stock Options
  15. Why Is Clovis (CLVS) Down 21% Since Last Earnings Report?
  16. Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting
  17. Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
  18. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  19. Did Changing Sentiment Drive Clovis Oncology’s Share Price Down A Worrying 66%?
  20. Clovis Oncology to Present at the Barclays Global Healthcare Conference